Clinical Trial Update: A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis [Phase 1, Phase 2]

View source ↗

Summary

Recruiting for a phase 1/2 study combining ruxolitinib with ulixertinib in patients with myelofibrosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis

Drugs mentioned

• Ruxolitinib (ruxolitinib)
• Ulixertinib (ulixertinib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Myelofibrosis | Phase 1, Phase 2 | Status: RECRUITING